Annual Total Liabilities
$56.82 M
+$48.28 M+565.32%
December 31, 2023
Summary
- As of March 6, 2025, OPRX annual total liabilities is $56.82 million, with the most recent change of +$48.28 million (+565.32%) on December 31, 2023.
- During the last 3 years, OPRX annual total liabilities has risen by +$46.47 million (+448.79%).
- OPRX annual total liabilities is now at all-time high.
Performance
OPRX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$50.73 M
-$1.13 M-2.17%
September 30, 2024
Summary
- As of March 6, 2025, OPRX quarterly total liabilities is $50.73 million, with the most recent change of -$1.13 million (-2.17%) on September 30, 2024.
- Over the past year, OPRX quarterly total liabilities has increased by +$42.91 million (+548.57%).
- OPRX quarterly total liabilities is now -10.71% below its all-time high of $56.82 million, reached on December 31, 2023.
Performance
OPRX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
OPRX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +565.3% | +548.6% |
| 3 y3 years | +448.8% | +428.2% |
| 5 y5 years | +761.4% | +330.8% |
OPRX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +565.3% | -10.7% | +820.8% |
| 5 y | 5-year | at high | +565.3% | -10.7% | +820.8% |
| alltime | all time | at high | >+9999.0% | -10.7% | >+9999.0% |
OptimizeRx Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $50.73 M(-2.2%) |
| Jun 2024 | - | $51.86 M(-3.7%) |
| Mar 2024 | - | $53.83 M(-5.3%) |
| Dec 2023 | $56.82 M(+565.3%) | $56.82 M(+626.4%) |
| Sep 2023 | - | $7.82 M(+42.0%) |
| Jun 2023 | - | $5.51 M(-28.7%) |
| Mar 2023 | - | $7.73 M(-9.5%) |
| Dec 2022 | $8.54 M(-11.1%) | $8.54 M(+35.5%) |
| Sep 2022 | - | $6.30 M(-5.0%) |
| Jun 2022 | - | $6.63 M(-6.4%) |
| Mar 2022 | - | $7.09 M(-26.2%) |
| Dec 2021 | $9.61 M(-7.2%) | $9.61 M(+22.6%) |
| Sep 2021 | - | $7.83 M(+12.7%) |
| Jun 2021 | - | $6.95 M(+21.1%) |
| Mar 2021 | - | $5.74 M(-44.6%) |
| Dec 2020 | $10.35 M(-12.1%) | $10.35 M(+22.3%) |
| Sep 2020 | - | $8.47 M(-32.6%) |
| Jun 2020 | - | $12.55 M(-0.4%) |
| Mar 2020 | - | $12.61 M(+7.1%) |
| Dec 2019 | $11.78 M(+78.5%) | $11.78 M(+58.7%) |
| Sep 2019 | - | $7.42 M(-4.0%) |
| Jun 2019 | - | $7.73 M(+32.9%) |
| Mar 2019 | - | $5.82 M(-11.8%) |
| Dec 2018 | $6.60 M(+86.2%) | $6.60 M(+158.0%) |
| Sep 2018 | - | $2.56 M(-10.1%) |
| Jun 2018 | - | $2.84 M(+16.6%) |
| Mar 2018 | - | $2.44 M(-31.2%) |
| Dec 2017 | $3.54 M(-3.4%) | $3.54 M(-5.8%) |
| Sep 2017 | - | $3.76 M(-6.1%) |
| Jun 2017 | - | $4.01 M(+3.7%) |
| Mar 2017 | - | $3.87 M(+5.4%) |
| Dec 2016 | $3.67 M | $3.67 M(+13.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $3.22 M(+13.4%) |
| Jun 2016 | - | $2.84 M(+11.4%) |
| Mar 2016 | - | $2.55 M(-24.3%) |
| Dec 2015 | $3.37 M(+39.4%) | $3.37 M(+9.5%) |
| Sep 2015 | - | $3.08 M(+35.1%) |
| Jun 2015 | - | $2.28 M(+4.5%) |
| Mar 2015 | - | $2.18 M(-9.8%) |
| Dec 2014 | $2.42 M(+5.9%) | $2.42 M(+58.9%) |
| Sep 2014 | - | $1.52 M(+2.7%) |
| Jun 2014 | - | $1.48 M(-22.5%) |
| Mar 2014 | - | $1.91 M(-16.3%) |
| Dec 2013 | $2.28 M(+196.5%) | $2.28 M(+201.5%) |
| Sep 2013 | - | $757.70 K(+6.4%) |
| Jun 2013 | - | $712.30 K(-5.2%) |
| Mar 2013 | - | $751.20 K(-2.5%) |
| Dec 2012 | $770.50 K(-40.9%) | $770.50 K(-13.4%) |
| Sep 2012 | - | $890.20 K(-13.1%) |
| Jun 2012 | - | $1.02 M(+7.9%) |
| Mar 2012 | - | $949.50 K(-27.1%) |
| Dec 2011 | $1.30 M(-29.7%) | $1.30 M(+76.3%) |
| Sep 2011 | - | $739.40 K(-60.3%) |
| Jun 2011 | - | $1.86 M(-0.6%) |
| Mar 2011 | - | $1.87 M(+1.1%) |
| Dec 2010 | $1.85 M(+4806.9%) | $1.85 M(+195.6%) |
| Sep 2010 | - | $627.40 K(+1.1%) |
| Jun 2010 | - | $620.80 K(+4366.2%) |
| Mar 2010 | - | $13.90 K(-63.2%) |
| Dec 2009 | $37.80 K(-82.6%) | $37.80 K(+220.3%) |
| Sep 2009 | - | $11.80 K(-75.6%) |
| Jun 2009 | - | $48.30 K(-75.0%) |
| Mar 2009 | - | $193.10 K(-11.3%) |
| Dec 2008 | $217.80 K(-44.1%) | $217.80 K |
| Dec 2007 | $389.90 K | - |
FAQ
- What is OptimizeRx annual total liabilities?
- What is the all time high annual total liabilities for OptimizeRx?
- What is OptimizeRx annual total liabilities year-on-year change?
- What is OptimizeRx quarterly total liabilities?
- What is the all time high quarterly total liabilities for OptimizeRx?
- What is OptimizeRx quarterly total liabilities year-on-year change?
What is OptimizeRx annual total liabilities?
The current annual total liabilities of OPRX is $56.82 M
What is the all time high annual total liabilities for OptimizeRx?
OptimizeRx all-time high annual total liabilities is $56.82 M
What is OptimizeRx annual total liabilities year-on-year change?
Over the past year, OPRX annual total liabilities has changed by +$48.28 M (+565.32%)
What is OptimizeRx quarterly total liabilities?
The current quarterly total liabilities of OPRX is $50.73 M
What is the all time high quarterly total liabilities for OptimizeRx?
OptimizeRx all-time high quarterly total liabilities is $56.82 M
What is OptimizeRx quarterly total liabilities year-on-year change?
Over the past year, OPRX quarterly total liabilities has changed by +$42.91 M (+548.57%)